IDH2 and myelodysplastic syndrome: Richard-Carpentier et al. reported the preliminary results of a phase II study designed to evaluate the efficacy and tolerability of enasidenib alone and in combination with azacytidine in patients with high-risk IDH2-mutated MDS [172].